Is it safe?
Can ABBV take a bad year?
AbbVie carries $64.3B of net debt at 3.64× EBITDA: a load its earnings can carry.
$64.3B
Net debt · as at Q2 2026 · between two and four years of EBITDA, normal for a stable business
- Net debt / EBITDA
- 3.64×
Net debt / EBITDA · 5.46× a year ago · the load is coming down
- Altman Z-score
- 2.36
Altman Z-score · grey zone, between 1.8 and 3
- Interest cover
- 5.79×
Interest cover · operating profit covers the interest bill several times over
Details›
- Total debtQ2 2026
- $70.8B
- Cash and short-term investments
- $6.57B
- Net debt
- $64.3B
- EBITDA, trailing twelve months
- $17.6B
- Operating profit, trailing twelve months
- $16.9B
- Total debt / EBITDA
- 4.01×
- Annualised volatilitytwo years of daily moves
- 27%
- Worst drawdown on file
- −45%
- Below its 52-week high
- −1.2%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers - General
Ranks #15 of 16 by Smart Score